Dexcel Pharma Executive and Leadership Team

Dan Oren, the President & Chief Executive Officer at Dexcel Pharma, directs the overarching corporate strategy and long-term vision for the organization. By overseeing the development of branded prescription drugs and generic portfolios, the President & Chief Executive Officer ensures the company maintains a competitive edge in the global pharmaceutical landscape. Dan Oren manages high-level relationships with international distribution partners across the U.S., U.K., and Germany to expand market reach. This leadership role involves constant evaluation of manufacturing capabilities to ensure compliance with rigorous international standards. Through the alignment of research initiatives with commercial goals, the President & Chief Executive Officer drives sustainable growth and operational excellence. By prioritizing innovation in oral solid dosage forms, Oren secures the company's position as a leader in the private pharmaceutical sector, consistently delivering value to patients and stakeholders worldwide.

Ilan Oren, the Co-Chief Executive Officer at Dexcel Pharma, architects the commercialization strategies for the company's extensive portfolio of OTC products and prescription medications. Focusing on the expansion of market presence within European and North American territories, the Co-Chief Executive Officer optimizes supply chain logistics to meet diverse regulatory requirements. Ilan Oren collaborates with internal teams to refine product development cycles, ensuring that manufacturing outputs align with current market demands. This executive role involves identifying new opportunities for growth through strategic partnerships and subsidiary management. By monitoring global pharmaceutical trends, the Co-Chief Executive Officer maintains the agility necessary to navigate complex international markets. Through the integration of efficient commercial processes, Oren strengthens the company's ability to deliver high-quality pharmaceutical solutions, ultimately enhancing the organization's footprint and ensuring consistent product availability across all key geographic regions.

Yaron Erez, the Chief Financial Officer & Vice President at Dexcel Pharma, executes the financial planning, budgeting, and capital allocation strategies necessary to sustain the company's manufacturing growth. Overseeing fiscal health across international markets, the Chief Financial Officer & Vice President manages the financial risks associated with global distribution and subsidiary operations. Yaron Erez directs the analysis of investment opportunities in new pharmaceutical technologies and production facilities. This leadership role involves providing the executive team with accurate financial insights to guide strategic expansion into the U.S. and European markets. By optimizing cost structures and revenue streams, the Chief Financial Officer & Vice President ensures the company maintains the liquidity required for long-term research and development. Through rigorous financial oversight and reporting, Erez supports the organization's stability and profitability, enabling the continued delivery of high-quality pharmaceutical products to a diverse and growing global patient base.

Ziv Teresh, the Chief Operating Officer & Vice President at Dexcel Pharma, architects the operational workflows and manufacturing processes that define the company's production of oral solid dosage forms. Overseeing the daily activities within the manufacturing facilities, the Chief Operating Officer & Vice President ensures that all production lines meet stringent quality and safety standards. Ziv Teresh manages the coordination between manufacturing, quality control, and logistics to ensure the timely delivery of over 85 products to international markets. This leadership role involves driving continuous improvement initiatives to enhance production efficiency and reduce operational waste. By supervising the technical teams responsible for product manufacturing, the Chief Operating Officer & Vice President maintains the high standards expected of a leading pharmaceutical company. Through the optimization of internal processes, Teresh ensures that the company's operational capacity remains aligned with the strategic goals of the organization, supporting consistent product availability.

Miri Peleg, the Chief Information Officer & Vice President at Dexcel Pharma, directs the digital transformation and technological infrastructure supporting the company's manufacturing and commercial operations. Overseeing the implementation of advanced data systems, the Chief Information Officer & Vice President ensures the integrity and security of information across all global subsidiaries. Miri Peleg manages the integration of enterprise resource planning tools to streamline the production of oral solid dosage forms. This leadership role involves aligning IT strategy with the broader business objectives to improve operational efficiency and data-driven decision-making. By modernizing digital platforms, the Chief Information Officer & Vice President supports the company's ability to scale production and distribution efforts effectively. Through the deployment of robust cybersecurity frameworks, Peleg protects critical intellectual property and maintains compliance with international data standards, ensuring that the technological foundation remains a core driver of the company's ongoing success.

Esther Hagai, the Chief Medical Officer at Dexcel Pharma, directs the clinical and medical affairs that validate the safety and efficacy of the company's branded prescription drugs and generics. Overseeing the medical review processes, the Chief Medical Officer ensures that all products comply with the regulatory requirements of the U.S., U.K., and other international markets. Esther Hagai manages the interaction between the company and medical professionals to provide accurate information regarding product applications and therapeutic benefits. This leadership role involves guiding the development of clinical documentation and supporting the regulatory approval process for new dosage forms. By maintaining high medical standards, the Chief Medical Officer ensures that the company's pharmaceutical offerings meet the needs of patients and healthcare providers. Through the oversight of medical compliance and safety monitoring, Hagai protects the company's reputation and contributes to the overall success of the product portfolio in competitive global markets.